CRBP - Corbus Pharmaceuticals Holdings, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue2,440.1951,911.424648.382
Cost of Revenue---
Gross Profit2,440.1951,911.424648.382
Operating Expenses
Research Development26,038.96515,436.7355,888.659
Selling General and Administrative8,964.0466,459.7473,613.416
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-32,562.816-19,985.058-8,853.693
Income from Continuing Operations
Total Other Income/Expenses Net141.204-13.6172.954
Earnings Before Interest and Taxes-32,421.612-19,998.675-8,850.739
Interest Expense---
Income Before Tax-32,421.612-19,998.675-8,850.739
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-32,421.612-19,998.675-8,850.739
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-32,421.612-19,998.675-8,850.739
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-32,421.612-19,998.675-8,850.739